Fighting Post-COVID and ME/CFS – development of curative therapies

Carmen Scheibenbogen, Judith Theresia Bellmann-Strobl, Cornelia Heindrich*, Kirsten Wittke, Elisa Stein, Christiana Franke, Harald Prüss, Hannah Preßler, Marie Luise Machule, Heinrich Audebert, Carsten Finke, Hanna Gwendolyn Zimmermann, Birgit Sawitzki, Christian Meisel, Markus Toelle, Anne Krueger, Anna C. Aschenbrenner, Joachim L. Schultze, Marc D. Beyer, Markus RalserMichael Mülleder, Leif Erik Sander, Frank Konietschke, Friedemann Paul, Silvia Stojanov, Lisa Bruckert, Dennis M. Hedderich, Franziska Knolle, Gabriela Riemekasten, Maria J.G.T. Vehreschild, Oliver A. Cornely, Uta Behrends, Susen Burock

*Corresponding author for this work
10 Citations (Scopus)


The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.

Original languageEnglish
Article number1194754
JournalFrontiers in medicine
Publication statusPublished - 2023

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

DFG Research Classification Scheme

  • 204-05 Immunology

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19

Cite this